MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Acceleron Pharma Company Profile (NASDAQ:XLRN)

Consensus Ratings for Acceleron Pharma (NASDAQ:XLRN) (?)
Ratings Breakdown: 8 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $50.33 (48.13% upside)

Analysts' Ratings History for Acceleron Pharma (NASDAQ:XLRN)
Show:
DateFirmActionRatingPrice TargetActions
6/29/2016Morgan StanleyReiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016BarclaysBoost Price TargetOverweight$40.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016FBR & Co.Reiterated RatingBuy$63.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016OppenheimerReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Janney Montgomery ScottUpgradeNeutral -> Buy$45.00 -> $39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/20/2016Credit SuisseInitiated CoverageOutperform$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015JMP SecuritiesBoost Price TargetMarket Outperform$52.00 -> $58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015Citigroup Inc.Boost Price TargetBuy$50.00 -> $52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Acceleron Pharma (NASDAQ:XLRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116($0.26)$0.14$8.70 million$18.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.09)($0.81)$15.70 million$3.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.46)($0.36)$4.38 million$4.16 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.49)($0.32)$4.23 million$5.72 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.43)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($0.23)($0.55)$3.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014($0.27)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.55)($0.54)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2014Q114($0.44)($0.30)$2.85 million$3.31 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2014Q413($0.08)($0.64)$13.66 million$11.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013($0.19)($5.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Acceleron Pharma (NASDAQ:XLRN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.43)($0.10)($0.27)
Q2 20163($0.59)($0.45)($0.52)
Q3 20162($0.63)($0.54)($0.59)
Q4 20162($0.69)($0.59)($0.64)
(Data provided by Zacks Investment Research)
Dividend History for Acceleron Pharma (NASDAQ:XLRN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Acceleron Pharma (NASDAQ:XLRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/20/2016John L KnopfCEOSell100,000$33.07$3,307,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2016Matthew L ShermanEVPSell26,000$32.00$832,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2016Steven D ErtelCOOSell32,270$32.00$1,032,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Corp /De/ CelgeneMajor ShareholderBuy800,000$40.00$32,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Matthew L. ShermanEVPSell6,000$23.28$139,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015John L. KnopfCEOSell19,000$24.38$463,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Kevin F. MclaughlinCFOSell7,000$24.38$170,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2015Matthew L. ShermanEVPSell2,000$33.24$66,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Ravindra KumarVPSell33,000$35.00$1,155,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Steven D. ErtelCOOSell2,000$33.61$67,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015John D. QuiselSVPSell5,500$33.35$183,425.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015John L. KnopfCEOSell19,000$30.20$573,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Kevin F. MclaughlinCFOSell6,500$30.16$196,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Matthew L ShermanEVPSell7,000$31.13$217,910.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015John D QuiselSVPSell5,500$30.83$169,565.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Matthew L ShermanEVPSell6,000$32.46$194,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Steven D ErtelCOOSell2,000$31.38$62,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015John D QuiselSVPSell5,500$30.00$165,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2015John L KnopfCEOSell19,000$29.70$564,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2015Kevin F MclaughlinCFOSell7,000$29.70$207,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Matthew L ShermanEVPSell7,000$31.54$220,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015John D QuiselSVPSell5,500$31.13$171,215.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Steven D ErtelCOOSell2,000$31.11$62,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015John L KnopfCEOSell19,000$32.51$617,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Kevin F MclaughlinCFOSell6,500$32.49$211,185.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Matthew L ShermanEVPSell7,000$32.37$226,590.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Steven D ErtelCOOSell2,000$31.49$62,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Matthew L ShermanEVPSell5,000$33.52$167,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Steven D ErtelCOOSell2,000$33.58$67,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2015John L KnopfCEOSell20,000$34.87$697,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2015Kevin F MclaughlinCFOSell7,000$34.88$244,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2015Matthew L ShermanEVPSell6,000$41.18$247,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015John D QuiselSVPSell9,500$41.00$389,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015John L KnopfCEOSell20,000$40.25$805,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Kevin F MclaughlinCFOSell6,500$40.25$261,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Matthew L ShermanSVPSell7,000$41.64$291,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Steven D ErtelSVPSell2,000$40.58$81,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Kevin F MclaughlinCFOSell2,000$40.66$81,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Ravindra KumarVPSell1,500$40.80$61,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2015John L KnopfCEOSell20,000$39.62$792,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2015Kevin F MclaughlinCFOSell5,000$39.46$197,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Ravindra KumarVPSell4,000$38.46$153,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Steven D ErtelSVPSell5,000$38.47$192,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Edwin M Kania JrDirectorSell54,350$38.00$2,065,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Matthew L ShermanSVPSell5,000$40.16$200,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014John D QuiselSVPSell4,000$41.35$165,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Jean GeorgeDirectorSell97,407$44.90$4,373,574.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014John L KnopfCEOSell20,000$43.99$879,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Kevin F MclaughlinCFOSell10,000$44.02$440,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Tom ManiatisDirectorSell23,400$45.00$1,053,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Ravindra KumarVPSell4,000$35.88$143,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Steven D ErtelSVPSell7,500$35.87$269,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Matthew L ShermanSVPSell5,082$33.76$171,568.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Ravindra KumarVPSell16,000$34.53$552,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2014Tom ManiatisDirectorSell23,400$35.00$819,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014John L KnopfCEOSell20,000$29.71$594,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Matthew L ShermanSVPSell5,082$29.50$149,919.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Kevin F MclaughlinCFOSell10,000$29.25$292,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Ravindra KumarVPSell11,000$29.89$328,790.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Steven D ErtelSVPSell10,000$29.66$296,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014John D QuiselSVPSell7,000$30.01$210,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Matthew L ShermanSVPSell5,000$25.48$127,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014John D QuiselSVPSell2,000$25.43$50,860.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014John L KnopfCEOSell20,000$24.46$489,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014Kevin F MclaughlinCFOSell10,000$24.48$244,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014John L KnopfCEOSell6,700$24.92$166,964.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Kevin F MclaughlinCFOSell3,300$24.90$82,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2014Matthew L ShermanSVPSell5,000$25.82$129,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Matthew L ShermanSVPSell2,500$29.62$74,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014John D QuiselSVPSell13,000$29.98$389,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014John L KnopfCEOSell17,500$29.78$521,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Kevin F MclaughlinCFOSell10,000$29.78$297,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Ravindra KumarVPSell9,000$29.97$269,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2014Matthew L ShermanSVPSell2,500$26.22$65,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2014John D QuiselSVPSell5,000$29.73$148,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2014Matthew L ShermanSVPSell7,500$28.99$217,425.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014John L KnopfCEOSell17,500$31.74$555,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Kevin F MclaughlinCFOSell10,000$31.72$317,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Ravindra KumarVPSell2,000$34.10$68,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Steven D ErtelSVPSell10,000$34.09$340,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2014Jean GeorgeDirectorSell10,491$35.01$367,289.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2014Jean GeorgeDirectorSell25,477$35.16$895,771.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2014Ravindra KumarVPSell7,000$35.00$245,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Matthew L ShermanSVPSell2,500$34.42$86,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014John D QuiselVPSell9,000$33.94$305,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2014Matthew L ShermanSVPSell7,500$33.23$249,225.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014John L KnopfCEOSell15,000$31.65$474,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Kevin F MclaughlinCFOSell10,000$31.65$316,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014John KnopfCEOSell15,000$31.52$472,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014John QuiselVPSell9,000$31.43$282,870.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Steven ErtelSVPSell10,000$31.52$315,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Corp /De/ Celgenemajor shareholderBuy1,100,000$42.86$47,146,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Jean GeorgeDirectorSell215,644$42.86$9,242,501.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2014Edwin Kania, Jr.DirectorSell1,000,000$32.05$32,050,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2014Ravindra KumarVPSell2,000$35.86$71,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2014Steven ErtelSVPSell2,500$35.87$89,675.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2014Corp /De/ CelgeneMajor ShareholderBuy300,000$50.00$15,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2013Corp /De/ CelgeneMajor ShareholderBuy666,667$15.00$10,000,005.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Acceleron Pharma (NASDAQ:XLRN)
DateHeadline
06/30/16 07:35 PMAcceleron Pharma Inc. (XLRN) Jumps 6.44% on June 28 - Equities.com
06/29/16 10:01 AMAcceleron Pharma Inc. (NASDAQ:XLRN) Company Rating and Target Watch - Telanagana Press
06/29/16 10:01 AMWere Analysts Bearish Acceleron Pharma Inc (NASDAQ:XLRN) This Week? - Press Telegraph
06/29/16 10:01 AMAcceleron Pharma Incorporated (NASDAQ:XLRN) Sellers Covered 4.22% of Their Shorts - Press Telegraph
06/29/16 06:21 AMAcceleron Announces Presentation of ACE-083 Phase 1 Healthy Volunteer Data at the 14th International Congress on Neuromuscular Disease - [at noodls] - June 29, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates ...
06/28/16 08:58 AMAcceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : June 28, 2016 -
06/27/16 04:28 AMStock Performance Focus on: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Press Telegraph
06/27/16 04:28 AMShare Update and Earnings Review for Acceleron Pharma Inc. (NASDAQ:XLRN) - Press Telegraph
06/27/16 04:28 AMNext Weeks Broker Price Targets For Acceleron Pharma Inc. (XLRN) - Fiscal Standard
06/25/16 10:58 AMStock Tracing Lower on the Week Acceleron Pharma, Inc. (NASDAQ:XLRN) - Engelwood Daily
06/25/16 10:58 AMCan Acceleron Pharma Inc. (NASDAQ:XLRN) Keep Up with Analyst Expectations? - Investor Newswire
06/24/16 09:58 AMAnalysts Confident In Acceleron Pharma's Drug Trial Outcomes - Benzinga
06/24/16 09:58 AMCovering the Bases on Acceleron Pharma Inc. (NASDAQ:XLRN): Where is the Stock Going? - Press Telegraph
06/23/16 08:10 PMAnalysts Confident In Acceleron Pharma's Drug Trial Outcomes
06/23/16 09:53 AMAcceleron Pharma, Inc. (NasdaqGM:XLRN) Stock Momentum Hits Strength - CML News
06/21/16 04:43 AMBarclays Maintains Acceleron Pharma Inc to Overweight with Price Target $42.00 - TheFounders Daily
06/21/16 04:43 AMAcceleron Pharma (XLRN) Is Today's Dead Cat Bounce Stock - TheStreet.com
06/20/16 08:42 AMMorning Alert: Acceleron Pharma, Inc. (NASDAQ:XLRN), Virco Mfg. Corporation (NASDAQ:VIRC), Rite Aid Corporation ... - KC Register
06/20/16 08:42 AMAcceleron Pharma, Inc. (NASDAQ:XLRN) Fell -5.29%: Incyte Corporation (NASDAQ:INCY), bluebird bio, Inc. (NASDAQ ... - KC Register
06/16/16 07:35 AMRecently Issued Stock Ratings For Acceleron Pharma Inc. (XLRN) - Fiscal Standard
06/14/16 04:25 AMAcceleron's Luspatercept Is All About Duration, And This Analyst Is Excited About Its Prospects
06/13/16 06:47 PMBarclays Raises Acceleron Price Target On Positive Luspatercept Data
06/13/16 04:06 PMACCELERON PHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/10/16 07:00 AMAcceleron Pharma Inc to Review Updated Luspatercept Results Presented at the 21st Congress of the European Hematology Association Call scheduled for 8:00 am ET today -
06/10/16 06:09 AMAcceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association - [at noodls] - June 10, 2016 - Longer term data with investigational drug luspatercept show sustained increases in hemoglobin levels, reduced transfusion burden, and improved patient reported quality of life measures ...
06/10/16 06:09 AMAcceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association - [at noodls] - June 10, 2016 - Preliminary results show that treatment with investigational drug luspatercept results in clinically meaningful increases in hemoglobin and durable transfusion independence in patients ...
06/10/16 06:02 AM7:02 am Acceleron Pharma & Celgene (CELG) announce prelim results from ongoing phase 2 extension study with luspatercept in patients with lower risk myelodysplastic syndromes at the 21st Congress of the E -
06/08/16 10:33 AMACCELERON PHARMA INC. (NASDAQ:XLRN) Financial Condition Compared to S&P 500 - CML News
06/07/16 07:41 PMWhich way Acceleron Pharma, Inc. (NASDAQ:XLRN) earnings may go - iStreetWire
06/07/16 03:18 PMAcceleron Pharma to Host Conference Call and Webcast to Review Updated Luspatercept Results Presented at the 21st Congress of the European Hematology Association - [at noodls] - June 7, 2016 Management to review highlights from presentations of ongoing Phase 2 clinical trials in MDS and beta-thalassemia CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a ...
06/06/16 03:34 PMACCELERON PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote o -
06/03/16 10:29 AMShare Rating Focus on Acceleron Pharma Inc. (NASDAQ:XLRN) - HNN
06/02/16 07:58 PMAcceleron Pharma Inc. (XLRN) Jumps 9.82% on June 02 - Equities.com - Acceleron Pharma Inc. (XLRN) Jumps 9.82% on June 02Equities.comAcceleron Pharma Inc. (XLRN) was among the biggest gainers on the Russell 2000 for Thursday June 02 as the stock popped 9.82% to $37.23, representing a gain of $3.33 per share. Some 407,972 shares traded hands on 4,169 trades, compared with an ...Top Stock in Session: Acceleron Pharma, Inc. (NASDAQ:XLRN)The Postall 2 news articles »
06/02/16 10:45 AMTarget Price and Stock Performance Rundown for Acceleron Pharma Inc. (NASDAQ:XLRN) - HNN - Target Price and Stock Performance Rundown for Acceleron Pharma Inc. (NASDAQ:XLRN)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Acceleron Pharma Inc. (NASDAQ:XLRN ...and more »
06/01/16 08:09 PMAcceleron Pharma Inc (NASDAQ:XLRN) Given Average Recommendation of “Buy” from Analysts - Let Me Know About This - Acceleron Pharma Inc (NASDAQ:XLRN) Given Average Recommendation of “Buy” from AnalystsLet Me Know About ThisAcceleron Pharma logo Acceleron Pharma Inc (NASDAQ:XLRN) has received a consensus recommendation of “Buy” from the ten ratings firms that are covering the firm. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating ...Acceleron Pharma Inc. (NASDAQ:XLRN) Stock Update & EstimatesStock Tick Tockall 3 news articles »
06/01/16 06:13 AMAcceleron Pharma to Participate in Two Healthcare Investor Conferences in June - [at noodls] - June 1, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates ...
05/28/16 01:23 AMStock Rating Review for Acceleron Pharma Inc. (NASDAQ:XLRN) - Wall Street Hints and News - Stock Rating Review for Acceleron Pharma Inc. (NASDAQ:XLRN)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1.31 on shares of Acceleron Pharma Inc. (NASDAQ:XLRN). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus ...and more »
05/27/16 08:08 PMMclaughlin Kevin F, SVP, CFO and Treasurer of Acceleron Pharma Inc (NASDAQ:XLRN) sells 25,300 shares - According to Acceleron Pharma Inc's most recent Form 4 filing with the SEC dated May 25 04:29 PM, company SVP, CFO and Treasurer, Mclaughlin Kevin F disclosed selling 25,300 shares at a cost of $34.00. At the time of this transaction (May 23), this trade ...
05/26/16 07:45 PMAcceleron Pharma Incorporated (NASDAQ:XLRN) Sellers Covered 4.64% of Their Shorts - Wall Street Hints and News - Acceleron Pharma Incorporated (NASDAQ:XLRN) Sellers Covered 4.64% of Their ShortsWall Street Hints and NewsThe short interest to Acceleron Pharma Incorporated's float is 6.82%. The stock is down 0.02% or $0.01 after the news, hitting $34.34 per share. About 370,584 shares traded hands or 3.81% up from the average. Acceleron Pharma Inc (NASDAQ:XLRN) has ...
05/26/16 07:45 PMAcceleron Pharma Inc. (NASDAQ:XLRN) One-Year Price Target At $47.33 - Investor Newswire - Acceleron Pharma Inc. (NASDAQ:XLRN) One-Year Price Target At $47.33Investor NewswireFirst Call has set a 52-week price target of $47.33 on Acceleron Pharma Inc. (NASDAQ:XLRN) stock after completion of its survey. For the approaching quarter, EPS estimate is set at $-0.53 and for underway fiscal at $-1.56. This estimate for next year ...and more »
05/26/16 06:52 AMTarget Check and Stock Performance Recap Acceleron Pharma Inc. (NASDAQ:XLRN) - Wall Street Hints and News - Target Check and Stock Performance Recap Acceleron Pharma Inc. (NASDAQ:XLRN)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Acceleron Pharma Inc.and more »
05/26/16 06:52 AMPerceptive Advisors LLC Increased Acceleron Pharma (NASDAQ:XLRN) by $13.70 Million as Shares Declined - CCH Daily News - Perceptive Advisors LLC Increased Acceleron Pharma (NASDAQ:XLRN) by $13.70 Million as Shares DeclinedCCH Daily NewsJoseph Edelman increased its stake in Acceleron Pharma (NASDAQ:XLRN) by 190.92% based on its latest 2016Q1 regulatory filing with the SEC. Perceptive Advisors Llc bought 527,000 shares as the company's stock declined 41.17% while stock markets ...and more »
05/26/16 06:52 AMInsiders Are Gradually Buying Acceleron Pharma, Inc. (NASDAQ:XLRN) - Wall Street Hints and News - Insiders Are Gradually Buying Acceleron Pharma, Inc. (NASDAQ:XLRN)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Acceleron Pharma, Inc. (NASDAQ:XLRN) have increased their position in the stock by 12.29% over the past 6 months. Insiders now own 16.10% of total outstanding shares. There are both legal and illegal ...and more »
05/21/16 06:39 PMAcceleron Pharma Inc. (NASDAQ:XLRN) One-Year Price Projection At $49.285 - RealistInvestor.com - Acceleron Pharma Inc. (NASDAQ:XLRN) One-Year Price Projection At $49.285RealistInvestor.comSell-side analysts are certain on the prospect of Acceleron Pharma Inc. (NASDAQ:XLRN) stock. As of 2016-05-20, the stock ABR stands at 1.31. This type of rating states that whenever a stock has a score of 5, investors should avoid investing in such stocks.and more »
05/20/16 07:06 PMAnalyst Rating Check on Acceleron Pharma Inc. (NASDAQ:XLRN) - Wall Street Hints and News - Analyst Rating Check on Acceleron Pharma Inc. (NASDAQ:XLRN)Wall Street Hints and NewsThis research may involve tracking what professional equity analysts think about the company. Currently, sell-side analysts have provided a consensus stock rating of 1.31 on shares of Acceleron Pharma Inc. (NASDAQ:XLRN). Analysts that cover the company ...and more »
05/19/16 06:22 AMAcceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association - [at noodls] - May 19, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates ...
05/17/16 07:47 PMETF’s with exposure to Acceleron Pharma, Inc. : May 18, 2016 -
05/16/16 07:05 AMAcceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : May 16, 2016 -
05/13/16 07:41 PMAcceleron Pharma Inc. (XLRN) Updated Broker Price Targets - Share Trading News - Acceleron Pharma Inc. (XLRN) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Acceleron Pharma Inc. (XLRN). The latest reports which are currently in issue on Friday 13th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...Consensus Rating Review for Acceleron Pharma Inc. (NASDAQ:XLRN)Wall Street Hints and Newsall 2 news articles »
05/13/16 01:38 AMAcceleron Pharma Inc. (XLRN) Drops 5.89% on May 11 - Equities.com - Acceleron Pharma Inc. (XLRN) Drops 5.89% on May 11Equities.comAcceleron Pharma Inc. (XLRN) was one of the Russell 2000's biggest losers for Wednesday May 11 as the stock slid 5.89% to $29.73, a loss of $-1.86 per share. Starting at an opening price of $31.45 a share, the stock traded between $29.68 and $31.82 ...
About Acceleron Pharma

Acceleron Pharma logoAcceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. Its segment operates through discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Its Luspatercept is designed to promote red blood cell production through a mechanism. It is developing sotatercept for the treatment of chronic kidney disease (CKD), a disorder characterized by anemia and a mineral and bone disorder that leads to bone loss and cardiovascular disease. Its Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. Its ACE-083 is designed for the treatment of focal muscle disorders, such as facioscapulohumeral dystrophy.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: XLRN
  • CUSIP:
Key Metrics:
  • Previous Close: $33.98
  • 50 Day Moving Average: $34.09
  • 200 Day Moving Average: $32.31
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.26B
  • Current Quarter EPS Consensus Estimate: $-1.56 EPS
Additional Links:
Acceleron Pharma (NASDAQ:XLRN) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha